(Total Views: 522)
Posted On: 04/29/2020 4:37:20 PM
Post# of 72440
The following article has some preliminary results on Remdesivir. Remdesivir looks like it will be the first CV19 treatment to hit the market. If mortality rates stay similar at 8% vs 11% placebo then there is definitely a need and an opportunity for better options. Brilacidin very well could end up being a better option since it would go after the virus, the bacterial infection, AND the inflammation.
================================================
Apr. 29, 2020 12:22 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Stephen Alpher, SA News Editor
The result from Gilead's (NASDAQ:GILD) trial of remdesivir is "quite good news," says "President" Anthony Fauci, with the data showing "clear cut significant positive effect in diminishing the time to recovery." The FDA, he says, is working with Gilead on the availability of the drug.
The Chinese study (negative results leaked last week, and details published this morning) was "underpowered, not adequate," says Fauci.
Fauci's comments seem to have put an extra charge into GILD - shares are now up 7% for the session.
CNBC's Meg Tirrell has details shared by Fauci on the more-important NIAID trial:
The primary endpoint was time to improvement, with those on remdesivir showing that in 11 days, and those on placebo 15 days.
The mortality rate on remdesivir was 8% vs. 11% for those on placebo.
Update: Dr. Fauci says the randomized, placebo-controlled study enrolled ~1,090 patients. The primary endpoint was the time to recovery and the ability to be discharged from the hospital. The independent Data Monitoring Committee informed him that remdesivir's clinical benefit was "clear-cut" and highly statistically significant (p<0.001). The drug's mortality benefit, while numerically better, is not yet statistically significant. Remdesivir represents a new standard-of-care for COVID-19. Studies testing remdesivir combined with other meds are next up.
================================================
Apr. 29, 2020 12:22 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Stephen Alpher, SA News Editor
The result from Gilead's (NASDAQ:GILD) trial of remdesivir is "quite good news," says "President" Anthony Fauci, with the data showing "clear cut significant positive effect in diminishing the time to recovery." The FDA, he says, is working with Gilead on the availability of the drug.
The Chinese study (negative results leaked last week, and details published this morning) was "underpowered, not adequate," says Fauci.
Fauci's comments seem to have put an extra charge into GILD - shares are now up 7% for the session.
CNBC's Meg Tirrell has details shared by Fauci on the more-important NIAID trial:
The primary endpoint was time to improvement, with those on remdesivir showing that in 11 days, and those on placebo 15 days.
The mortality rate on remdesivir was 8% vs. 11% for those on placebo.
Update: Dr. Fauci says the randomized, placebo-controlled study enrolled ~1,090 patients. The primary endpoint was the time to recovery and the ability to be discharged from the hospital. The independent Data Monitoring Committee informed him that remdesivir's clinical benefit was "clear-cut" and highly statistically significant (p<0.001). The drug's mortality benefit, while numerically better, is not yet statistically significant. Remdesivir represents a new standard-of-care for COVID-19. Studies testing remdesivir combined with other meds are next up.
(3)
(0)Scroll down for more posts ▼
